Ameliorative effects of SkQ1 eye drops on cataractogenesis in senescence-accelerated OXYS rats
- 258 Downloads
Antioxidant supplements have been suggested as a strategy to decrease the risk of age-related cataract, but there is no evidence that antioxidants can reduce the signs of the disease. Recently, we showed that the mitochondrial antioxidant SkQ1 can partially reverse cataract signs in senescence-accelerated OXYS rats. The aim of the present study was the histomorphological examination of the influence of SkQ1 eye drops on the cataract development in OXYS rats.
OXYS rats received SkQ1 eye drops (250 nM) from 9 to 12 months of age. Ophthalmoscopic examination was carried out before and after treatment. Light and electron microscopy were used for histomorphological examination. Expression of the Cryaa and Cryab genes was determined using real-time PCR. αB-crystallin expression was detected using Western blotting.
SkQ1 completely prevented the cataract development in OXYS rats, and in some of the animals diminished the signs of the disease. Light and electron microscopy showed that SkQ1 attenuated the (typical for cataract) alterations in the lens capsule and epithelial cells, ameliorated disturbances of the hexagonal packing geometry of lens fibers, and improved ultrastructure of the epithelial cells. The levels of mRNA of α-crystallins genes which encode small heat shock proteins αA- and αB-crystallin that play a central role in maintaining lens transparency were significantly lower in the OXYS rats’ lenses than in Wistar rats (control). SkQ1 normalized the level of mRNA of Cryaa, and significantly increased the level of Cryab mRNA as well as αB-crystallin protein in the lens of OXYS rats to the level of the control Wistar rats.
SkQ1 eye drops hold promise as a treatment of cataract.
KeywordsCataract Mitochondria-targeted antioxidant SkQ1 Alpha-crystallin OXYS rats
Microscopy was performed at the Microscopy Center of the Institute of Cytology and Genetics, SB RAS, Russia. This study was supported by the Russian Foundation for Basic Research (Grant # 14-04-00376) and by budgetary project No 53.2.3.
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
- 1.Chang JR, Koo E, Agrón E, Hallak J, Clemons T, Azar D, Sperduto RD, Ferris FL 3rd, Chew EY (2011) Age-related Eye Disease Study Group. Risk factors associated with incident cataracts and cataract surgery in the Age-related Eye Disease Study (AREDS): AREDS report number 32. Ophthalmology 118(11):2113–2119PubMedCentralPubMedCrossRefGoogle Scholar
- 3.Gritz DC, Srinivasan M, Smith SD, Kim U, Lietman TM, Wilkins JH, Priyadharshini B, John RK, Aravind S, Prajna NV, Duraisami Thulasiraj R, Whitcher JP (2006) The antioxidants in prevention of cataracts study: effects of antioxidant supplements on cataract progression in South India. Br J Ophthalmol 90(7):847–851PubMedCentralPubMedCrossRefGoogle Scholar
- 4.Mathew MC, Ervin AM, Tao J, Davis RM (2012) Antioxidant vitamin supplementation for preventing and slowing the progression of age-related cataract. Cochrane Database Syst Rev 6:CD004567. doi: 10.1002/14651858.CD004567.pub2
- 5.Chew EY, Sangiovanni JP, Ferris FL, Wong WT, Agron E, Clemons TE, Sperduto R, Danis R, Chandra SR, Blodi BA, Domalpally A, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Friberg TR, Rosenfeld PJ, Toth CA, Bernstein P (2013) Age-related Eye Disease Study 2 (AREDS2) Research Group. Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report No. 4. JAMA Ophthalmol 131(7):843–850PubMedCrossRefGoogle Scholar
- 7.Skulachev MV, Antonenko YN, Anisimov VN, Chernyak BV, Cherepanov DA, Chistyakov VA, Egorov MV, Kolosova NG, Korshunova GA, Lyamzaev KG, Plotnikov EY, Roginsky VA, Savchenko AY, Severina II, Severin FF, Shkurat TP, Tashlitsky VN, Shidlovsky KM, Vyssokikh MY, Zamyatnin AA Jr, Zorov DB, Skulachev VP (2011) Mitochondrial-targeted plastoquinone derivatives. Effect on senescence and acute age-related pathologies. Curr Drug Targets 12(6):800–826PubMedCrossRefGoogle Scholar
- 8.Neroev VV, Archipova MM, Bakeeva LE, Fursova AZ, Grigorian EN, Grishanova AY, Iomdina EN, Ivashchenko ZN, Katargina LA, Khoroshilova-Maslova IP, Kilina OV, Kolosova NG, Kopenkin EP, Korshunov SS, Kovaleva NA, Novikova YP, Philippov PP, Pilipenko DI, Robustova OV, Saprunova VB, Senin II, Skulachev MV, Sotnikova LF, Stefanova NA, Tikhomirova NK, Tsapenko IV, Shchipanova AI, Zinovkin RA, Skulachev VP (2008) Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 4. Age-related eye disease. SkQ1 returns vision to blind animals. Biochemistry (Mosc) 73:1317–1328CrossRefGoogle Scholar
- 16.Markovets AM, Saprunova VB, Zhdankina AA, Fursova AZ, Bakeeva LE, Kolosova NG (2011) Alterations of retinal pigment epithelium cause AMD-like retinopathy in senescence-accelerated OXYS rats. Aging (Albany NY) 3:44–54Google Scholar
- 17.Obukhova LA, Skulachev VP, Kolosova NG (2009) Mitochondria-targeted antioxidant SkQ1 inhibits age-dependent involution of the thymus in normal and senescence-prone rats. Aging (Albany NY) 1:389–401Google Scholar
- 24.Snytnikova OA, Tsentalovich YP, Stefanova NA, Fursova AZ, Kaptein R, Sagdeev RZ, Kolosova NG (2012) The therapeutic effect of mitochondria-targeted antioxidant SkQ1 and Cistanche deserticola is associated with increased levels of tryptophan and kynurenine in the rat lens. Dokl Biochem Biophys 447:300–303PubMedCrossRefGoogle Scholar
- 26.Skulachev VP, Anisimov VN, Antonenko YN, Bakeeva LE, Chernyak BV, Erichev VP, Filenko OF, Kalinina NI, Kapelko VI, Kolosova NG, Kopnin BP, Korshunova GA, Lichinitser MR, Obukhova LA, Pasyukova EG, Pisarenko OI, Roginsky VA, Ruuge EK, Senin II, Severina II, Skulachev MV, Spivak IM, Tashlitsky VN, Tkachuk VA, Vyssokikh MY, Yaguzhinsky LS, Zorov DB (2009) An attempt to prevent senescence: a mitochondrial approach. Biochim Biophys Acta 1787(5):437–461PubMedCrossRefGoogle Scholar